{"analyses":[{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"98.89","ciUpperLimit":"0.89","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A over Treatment C","nonInferiorityType":"SUPERIORITY","pValue":"0.0010","paramType":"Hazard Ratio (HR)","paramValue":"0.60","statisticalMethod":"Stratified Log-Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Insufficient number of participants with events.","groupId":"OG001","lowerLimit":"22.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"323"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"Overall Survival is defined as the time between the date of randomization and the date of death due to any cause. For participants that are alive, their survival time will be censored at the date of last contact date (or \"last known alive date\").","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD","id":"OG000","title":"Treatment A"},{"description":"Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle","id":"OG001","title":"Treatment C"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants of treatment A and treatment C","reportingStatus":"POSTED","timeFrame":"From randomization date to death date (Up to 31 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}